Study of a new drug IMC-P115C for advanced PRAME-positive cancers
Part of Cancer clinical trials.
This trial tests an experimental drug, IMC-P115C, for people with advanced cancers that have a specific marker called PRAME and a genetic type HLA-A*02:01. It may be an option if other treatments have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumors that have spread or cannot be removed by surgery.
- You have tried other treatments, or cannot take them due to side effects.
- You have a specific genetic marker (HLA-A*02:01) and your tumor tests positive for PRAME.
- You are in good enough health to perform daily activities (ECOG 0 or 1).
- You must use effective birth control if you or your partner could have children.
- You do not have untreated or spreading brain tumors, serious lung/heart disease, or certain other health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called IMC-R117C for people with certain advanced cancers. It aims to see if the drug can shrink tumors or slow cancer growth.
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
This is an early-stage trial testing a new drug called CRPA1A2 that trains your immune cells to fight certain cancers. The drug targets tumors that have specific genetic markers (MAGE-A1 and HLA-A*02:01). You may qualify if you have advanced cancer that hasn't responded to standard treatments.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.